Raajit K. Rampal, MD, PhD, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses investigational agents in myeloproliferative neoplasms (MPNs).

The MDM2 inhibitor idasanutlin (RG7388) is being looked at in an ongoing phase II trial (NCT03287245) to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of the agent for the treatment of patients with polycythemia vera who are resistant to or intolerant of hydroxyurea. Idasanutlin demonstrated promising preclinical and phase I clinical trial (NCT02407080) activity for this patient population, says Rampal.

In myelofibrosis, the August 2019 approval of fedratinib (Inrebic) was a revolutionary addition to the armamentarium, explains Rampal.

Other investigational compounds in myelofibrosis are currently being explored in clinical trials, concludes Rampal.

OncLive TV

® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers. 

Myeloproliferative Neoplasms

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.

Memorial Sloan Kettering Cancer Center 

Cancer Centers

Partner

Raajit K. Rampal, MD, PhD, discusses investigational agents in myeloproliferative neoplasms.

Dr. Rampal on Investigational Agents in MPNs